Redmile Group, LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Redmile Group, LLC reported 62 stock positions worth $1.4 billion. Its top holding was Scholar Rock (SRRK) at 13.7% of the portfolio, followed by Krystal Biotech (KRYS, 8.2%) and Nurix Therapeutics (NRIX, 5.5%). Compared with Q3 2024, it opened 3 new positions, sold out of 4, added to 9 and reduced 40. The biggest buy was Replimune (REPL, shares +3%) and the biggest sale an exit from Augmedix (AUGX).
- Most Recent 13F
- Q2 2026
- Location
- LARKSPUR, CA
- CIK
- 0001425738
- Portfolio Value
- $1.4B (Q4 2024)
- SEC Filing
- 0001104659-25-014154 ↗ filed Feb 14, 2025
Holdings Value
Holdings 62 stocks · $1.4B
| SRRK Scholar Rock Holding Corp. | 13.70% | 4,549,881 | $196.6M | Reduce -13.2% |
| KRYS Krystal Biotech Inc. | 8.22% | 753,175 | $118.0M | Reduce -7.0% |
| NRIX Nurix Therapeutics Inc. | 5.50% | 4,192,627 | $79.0M | Reduce -2.1% |
| ZYME Zymeworks Inc. | 4.94% | 4,840,463 | $70.9M | Reduce -5.1% |
| FOLD Amicus Therapeutics Inc. | 4.63% | 7,054,890 | $66.5M | Reduce -14.4% |
| REPL Replimune Group Inc. | 4.14% | 4,905,527 | $59.4M | Add +2.6% |
| IMNM Immunome Inc. | 3.57% | 4,828,026 | $51.3M | Reduce -1.3% |
| STOK Stoke Therapeutics Inc. | 3.53% | 4,593,629 | $50.7M | Reduce -2.5% |
| LIVN Livanova PLC | 3.37% | 1,043,539 | $48.3M | Add +19.3% |
| KYMR Kymera Therapeutics Inc. | 3.09% | 1,100,432 | $44.3M | Reduce -21.0% |
| PLRX Pliant Therapeutics Inc. | 2.66% | 2,895,478 | $38.1M | Reduce -9.4% |
| BEAM Beam Therapeutics Inc. | 2.64% | 1,528,567 | $37.9M | Reduce -5.1% |
| RGNX Regenxbio Inc. | 2.58% | 4,794,780 | $37.1M | Reduce -2.0% |
| AKRO Akero Therapeutics Inc. | 2.39% | 1,235,209 | $34.4M | Reduce -11.0% |
| BHVN Biohaven Ltd. | 2.35% | 904,496 | $33.8M | Reduce -12.5% |
| ANNX Annexon Inc. | 2.25% | 6,300,644 | $32.3M | Reduce -2.0% |
| ADCT Adc Therapeutics SA | 2.17% | 15,666,731 | $31.2M | Reduce -0.0% |
| NGNE Neurogene Inc. | 2.10% | 1,319,763 | $30.2M | Add +36.9% |
| BSX Boston Scientific Corp. | 1.95% | 312,683 | $27.9M | Reduce -5.5% |
| COGT Cogent Biosciences Inc. | 1.93% | 3,554,836 | $27.7M | Reduce -20.7% |
| ABSI Absci Corp. | 1.51% | 8,253,316 | $21.6M | No change |
| FATE Fate Therapeutics Inc. | 1.48% | 12,872,946 | $21.2M | Reduce -2.3% |
| IGMS Igm Biosciences Inc. | 1.26% | 2,952,131 | $18.0M | Reduce -3.9% |
| ETNB 89BIO Inc. | 1.18% | 2,167,176 | $16.9M | Add +38.0% |
| SLN Silence Therapeutics PLC-ADR | 1.15% | 2,399,317 | $16.5M | Add +26.3% |
| IDYA Ideaya Biosciences Inc. | 1.11% | 619,300 | $15.9M | Reduce -9.1% |
| CLDX Celldex Therapeutics Inc. | 1.08% | 615,775 | $15.6M | Reduce -6.3% |
| ESTA Establishment Labs Holdings | 1.03% | 320,149 | $14.7M | Add +22.3% |
| IMVT Immunovant Inc. | 0.99% | 571,824 | $14.2M | Reduce -11.0% |
| CBLL Ceribell Inc. | 0.79% | 435,239 | $11.3M | New |
| SYK Stryker Corp. | 0.77% | 30,676 | $11.0M | Reduce -6.3% |
| RAPT THERAPEUTICS INC | 0.71% | 6,475,317 | $10.2M | Add +1183.4% |
| BNTX Biontech SE-ADR | 0.66% | 83,471 | $9.5M | Reduce -46.0% |
| ISRG Intuitive Surgical Inc. | 0.62% | 16,943 | $8.8M | Reduce -36.5% |
| KROS Keros Therapeutics Inc. | 0.61% | 552,506 | $8.7M | No change |
| NUVB Nuvation Bio Inc. | 0.56% | 3,031,009 | $8.1M | No change |
| ARDX Ardelyx Inc. | 0.56% | 1,576,259 | $8.0M | Reduce -5.1% |
| ORKA Oruka Therapeutics Inc. | 0.56% | 411,728 | $8.0M | No change |
| VERV Verve Therapeutics Inc. | 0.52% | 1,318,164 | $7.4M | Reduce -4.7% |
| STTK Shattuck Labs Inc. | 0.47% | 5,539,724 | $6.7M | Reduce -1.4% |
| FDMT 4D Molecular Therapeutics Inc. | 0.46% | 1,196,910 | $6.7M | Reduce -5.2% |
| ALXO Alx Oncology Holdings Inc. | 0.43% | 3,689,611 | $6.2M | Reduce -3.8% |
| PEN Penumbra Inc. | 0.43% | 25,743 | $6.1M | Add +85.9% |
| PRME Prime Medicine Inc. | 0.42% | 2,074,350 | $6.1M | No change |
| ATRA Atara Biotherapeutics Inc. | 0.41% | 441,701 | $5.9M | Reduce -2.3% |
| CYTK Cytokinetics Inc. | 0.30% | 92,598 | $4.4M | Reduce -4.7% |
| STXS Stereotaxis Inc. | 0.29% | 1,799,465 | $4.1M | Reduce -14.7% |
| ALLK Allakos LLC | 0.25% | 3,015,097 | $3.6M | Reduce -2.0% |
| ATXS Astria Therapeutics Inc. | 0.22% | 346,278 | $3.1M | Add +11.4% |
| ACIU Ac Immune SA | 0.19% | 1,034,299 | $2.8M | Reduce -39.0% |
| RPTX Repare Therapeutics Inc. | 0.17% | 1,916,089 | $2.5M | Reduce -1.4% |
| PODD Insulet Corp. | 0.17% | 9,559 | $2.5M | New |
| SLDB Solid Biosciences Inc. | 0.17% | 615,246 | $2.5M | New |
| BOLD Boundless Bio Inc. | 0.15% | 740,204 | $2.1M | Reduce -27.7% |
| LVTX Lava Therapeutics NV | 0.14% | 2,074,372 | $2.0M | No change |
| ACHL Achilles Therapeutics PL-ADR | 0.13% | 1,608,089 | $1.8M | No change |
| XERS Xeris Biopharma Holdings Inc. | 0.11% | 451,099 | $1.5M | Reduce -56.9% |
| IVVD Invivyd Inc. | 0.09% | 3,012,254 | $1.3M | Reduce -1.7% |
| ALLOVIR INC | 0.06% | 1,907,969 | $801K | No change |
| ADAPY Adaptimmune Therapeutics-ADR | 0.03% | 715,607 | $385K | No change |
| VTYX Ventyx Biosciences Inc. | 0.02% | 124,178 | $272K | Reduce -94.1% |
| HOOK Hookipa Pharma Inc. | 0.01% | 106,376 | $214K | No change |
Portfolio Sells Q3 2024 → Q4 2024
| AUGX Augmedix Inc. | Sold out | 0.00% | −2.27 |
| CTLT Catalent Inc. | Sold out | 0.00% | −2.13 |
| IGMS Igm Biosciences Inc. | Reduce -3.9% | 1.26% | −1.74 |
| FATE Fate Therapeutics Inc. | Reduce -2.3% | 1.48% | −1.24 |
| COGT Cogent Biosciences Inc. | Reduce -20.7% | 1.93% | −0.92 |
| KYMR Kymera Therapeutics Inc. | Reduce -21.0% | 3.09% | −0.80 |
| ADCT Adc Therapeutics SA | Reduce -0.0% | 2.17% | −0.73 |
| BHVN Biohaven Ltd. | Reduce -12.5% | 2.35% | −0.69 |
| STTK Shattuck Labs Inc. | Reduce -1.4% | 0.47% | −0.69 |
| IMNM Immunome Inc. | Reduce -1.3% | 3.57% | −0.64 |
| FOLD Amicus Therapeutics Inc. | Reduce -14.4% | 4.63% | −0.56 |
| KRYS Krystal Biotech Inc. | Reduce -7.0% | 8.22% | −0.47 |
| RGNX Regenxbio Inc. | Reduce -2.0% | 2.58% | −0.44 |
| BNTX Biontech SE-ADR | Reduce -46.0% | 0.66% | −0.42 |
| FDMT 4D Molecular Therapeutics Inc. | Reduce -5.2% | 0.46% | −0.34 |
| VTYX Ventyx Biosciences Inc. | Reduce -94.1% | 0.02% | −0.25 |
| CLDX Celldex Therapeutics Inc. | Reduce -6.3% | 1.08% | −0.23 |
| RPTX Repare Therapeutics Inc. | Reduce -1.4% | 0.17% | −0.22 |
| ACIU Ac Immune SA | Reduce -39.0% | 0.19% | −0.18 |
| GRITSTONE BIO INC | Sold out | 0.00% | −0.17 |
| IDYA Ideaya Biosciences Inc. | Reduce -9.1% | 1.11% | −0.16 |
| NRIX Nurix Therapeutics Inc. | Reduce -2.1% | 5.50% | −0.16 |
| ISRG Intuitive Surgical Inc. | Reduce -36.5% | 0.62% | −0.16 |
| CABA Cabaletta Bio Inc. | Sold out | 0.00% | −0.12 |
| ARDX Ardelyx Inc. | Reduce -5.1% | 0.56% | −0.12 |
| IMVT Immunovant Inc. | Reduce -11.0% | 0.99% | −0.09 |
| IVVD Invivyd Inc. | Reduce -1.7% | 0.09% | −0.09 |
| XERS Xeris Biopharma Holdings Inc. | Reduce -56.9% | 0.11% | −0.07 |
| BOLD Boundless Bio Inc. | Reduce -27.7% | 0.15% | −0.06 |
| CYTK Cytokinetics Inc. | Reduce -4.7% | 0.30% | +0.00 |
| ANNX Annexon Inc. | Reduce -2.0% | 2.25% | +0.01 |
| ALXO Alx Oncology Holdings Inc. | Reduce -3.8% | 0.43% | +0.02 |
| STXS Stereotaxis Inc. | Reduce -14.7% | 0.29% | +0.03 |
| AKRO Akero Therapeutics Inc. | Reduce -11.0% | 2.39% | +0.05 |
| SYK Stryker Corp. | Reduce -6.3% | 0.77% | +0.07 |
| STOK Stoke Therapeutics Inc. | Reduce -2.5% | 3.53% | +0.12 |
| VERV Verve Therapeutics Inc. | Reduce -4.7% | 0.52% | +0.12 |
| ALLK Allakos LLC | Reduce -2.0% | 0.25% | +0.14 |
| ATRA Atara Biotherapeutics Inc. | Reduce -2.3% | 0.41% | +0.19 |
| BSX Boston Scientific Corp. | Reduce -5.5% | 1.95% | +0.31 |
| BEAM Beam Therapeutics Inc. | Reduce -5.1% | 2.64% | +0.32 |
| PLRX Pliant Therapeutics Inc. | Reduce -9.4% | 2.66% | +0.55 |
| ZYME Zymeworks Inc. | Reduce -5.1% | 4.94% | +1.17 |
| SRRK Scholar Rock Holding Corp. | Reduce -13.2% | 13.70% | +11.23 |
Portfolio Buys Q3 2024 → Q4 2024
| REPL Replimune Group Inc. | Add +2.6% | 4.14% | +1.05 |
| CBLL Ceribell Inc. | New | 0.79% | +0.79 |
| LIVN Livanova PLC | Add +19.3% | 3.37% | +0.66 |
| RAPT THERAPEUTICS INC | Add +1183.4% | 0.71% | +0.65 |
| ETNB 89BIO Inc. | Add +38.0% | 1.18% | +0.50 |
| ESTA Establishment Labs Holdings | Add +22.3% | 1.03% | +0.36 |
| PEN Penumbra Inc. | Add +85.9% | 0.43% | +0.27 |
| PODD Insulet Corp. | New | 0.17% | +0.17 |
| SLDB Solid Biosciences Inc. | New | 0.17% | +0.17 |
| ATXS Astria Therapeutics Inc. | Add +11.4% | 0.22% | +0.01 |
| NGNE Neurogene Inc. | Add +36.9% | 2.10% | −0.28 |
| SLN Silence Therapeutics PLC-ADR | Add +26.3% | 1.15% | −0.88 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 39 | $1.5B | SRRK, KRYS, STOK, IMNM, NRIX |
| Q1 2026 | 35 | $1.5B | SRRK, KRYS, STOK, IMNM, NRIX |
| Q4 2025 | 34 | $1.4B | SRRK, KRYS, NRIX, STOK, IMNM |
| Q3 2025 | 40 | $1.0B | SRRK, KRYS, STOK, ZYME, ADCT |
| Q2 2025 | 48 | $939.6M | SRRK, KRYS, ZYME, STOK, IMNM |
| Q1 2025 | 56 | $1.1B | SRRK, KRYS, FOLD, ZYME, NRIX |
| Q4 2024 | 62 | $1.4B | SRRK, KRYS, NRIX, ZYME, FOLD |
| Q3 2024 | 63 | $1.7B | KRYS, NRIX, FOLD, IMNM, KYMR |
| Q2 2024 | 63 | $1.7B | KRYS, FOLD, NRIX, STOK, IMNM |
| Q1 2024 | 77 | $2.7B | KRYS, FOLD, IMNM, SRRK, FATE |